#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic granulomatous disease Congenital absence of bile ducts Haemophilia B without inhibitors Cutaneous T-cell lymphoma Primary adrenal insufficiency Cardiomyopathy Glycogen storage disease type I Essential thrombocythaemia Leukoencephalopathy Polycythaemia vera Netherton's syndrome Neuronal ceroid lipofuscinosis Infantile apnoea Factor VIII deficiency Head and neck cancer More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma – Diagnostics Familial haemophagocytic lymphohistiocytosis – Treatment Prolymphocytic leukaemia Breast angiosarcoma – Basic Information Netherton’s syndrome KBG syndrome – Life with Disease Small intestine leiomyosarcoma – Basic Information Haemophilia B with anti factor IX – Trials in Disease Hereditary neuropathic amyloidosis – Diagnostics Turner’s syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    GSK5764227 Dronedarone Nanatinostat Valproate Semisodium Tebipenem Pivoxil Hydrobromide Bromocriptine Tezepelumab Promazine Hydrochloride Enzalutamide ACARBOSE Vixarelimab Sonelokimab Sildenafil Citrate Favezelimab Dapansutrile Elamipretide Trihydrochloride Diltiazem Methohexital Sodium Collagenase Cemdisiran More therapies…

    Learn about Your Condition

    Genital herpes Biliary tract operation Dyskinesia Henoch-Schonlein purpura Krabbe's disease Paraganglion neoplasm Complicated appendicitis Candida infection Lymphocytic leukaemia Factor VIII deficiency Lichenoid keratosis Metastases to meninges Anal cancer stage II Congenital ureteric anomaly Uveal melanoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Theageneio Cancer Hospital

Theageneio Cancer Hospital

Sugwlzjoh Agqt 2z Tefaypjbabdmf 5bh 3vb Gdhdie

Want to learn more about this study or check if you can participate? Contact us.

  • Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

    Recruiting

    3 1 1
    Investigated Drugs:
    • [4-(METHYL-1H-PYRAZOL-4-YL)-BENZYL]-(6[7-(3-PYRROLIDIN-1-YL-PROPOXY)-IMIDAZO[1,2-A]PYRIDIN-3-YL]-PYRIMIDIN-4-YL]-AMINE
    • Imatinib Mesilate
    Finland France Germany Greece Hungary Italy +7

  • Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

    Recruiting

    2 1 1
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    • Human Normal Immunoglobulin (Iv)
    • Tocilizumab
    France Greece Hungary Portugal Spain Sweden

  • Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Adagrasib
    • Cetuximab
    • Dexamethasone
    Belgium France Germany Greece Hungary Italy +5

  • Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Cevostamab
    • Carfilzomib
    • Elotuzumab
    Czechia Denmark France Germany Greece Italy +2

  • Study of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Bevacizumab
    • Tipiracil
    • Trifluridine
    Belgium Germany Greece Portugal Spain

  • EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Drugs:
    • Resiquimod Sulfate
    • Pembrolizumab
    Austria Belgium Bulgaria France Germany Greece +6

  • JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

    Recruiting

    3 1 1
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    • Teclistamab
    France Germany Greece Italy The Netherlands Norway +1

  • Study of belantamab mafodotin with drug combination in adults aged 18 years and older with relapsed or refractory multiple myeloma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Belantamab Mafodotin
    • Carfilzomib
    • Bortezomib
    France Germany Greece The Netherlands Spain

  • Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Hydroxocobalamin
    • Sotorasib
    • Betamethasone Sodium Phosphate Ph. Eur
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Study of icotrokinra for adults with moderately to severely active Crohn’s disease

    Recruiting

    4 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7
1 2 3 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!